Article Text

Download PDFPDF
Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson’s disease
  1. K Hamada1,
  2. M Hirayama1,
  3. H Watanabe1,
  4. R Kobayashi1,
  5. H Ito1,
  6. T Ieda2,
  7. Y Koike3,
  8. G Sobue1
  1. 1Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
  2. 2Department of Neurology, Yokkaichi Municipal Hospital, Yokkaichi, Japan
  3. 3Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan
  1. Correspondence to:
 Dr G Sobue, Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya 466–8550, Japan;
 sobueg{at}med.nagoya-u.ac.jp

Abstract

Objectives: To elucidate the factors associated with severity of cardiac sympathetic nerve involvement in idiopathic Parkinson’s disease (PD).

Methods:123I-metaiodobenzylguanidine uptake was examined in 88 patients with PD. The ratio of the uptake in the heart (H) to that in the mediastinum (M) (the H/M ratio) was calculated and correlated with age at onset, age at examination, and disease severity and duration. Twenty five healthy people were also examined as a control.

Results: There was a mild but significant negative correlation between H/M ratio and age at onset (early, r = −0.33, p = 0.002; delayed, r = −0.34, p = 0.001) and between Hoehn and Yahr (H-Y) stage (early, r = −0.30, p = 0.006; delayed, r = −0.32, p = 0.003). There was no significant correlation between disease duration and H/M ratio. When patients with PD were classified into four subgroups on the basis of age at onset (> 62 or < 62 years) and disease severity (H-Y > III or H-Y ⩽ II), the median H/M ratio of the older and more severe group was significantly lower than that of the younger and less severe group (p = 0.005).

Conclusion: This study suggests that late onset, high severity PD is associated with myocardial sympathetic dysfunction.

  • 123I-metaiodobenzylguanidine
  • Parkinson’s disease
  • age
  • onset
  • H-Y, Hoehn and Yahr
  • MIBG, 123I-metaiodobenzylguanidine
  • PD, Parkinson’s disease

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes